A Phase 1 interventional study of Midazolam and Selexipag in Healthy Subjects, sponsored by Actelion. Completed at 1 site in France. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-10-13.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary purpose of this study is to evaluate the effect of repeated doses of selexipag on the pharmacokinetics of a single oral dose of midazolam (i.e., how long and how much midazolam is present in the blood)
In order to exclude an inductive effect of selexipag in the gastrointestinal tract, this study aims at investigating the effect of selexipag on the PK of midazolam, a sensitive substrate of both hepatic and intestinal cytochrome P450 3A4 (CYP3A4).
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
First submitted before Actelion became part of Johnson & Johnson.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects participate in two study periods: During the first period, they receive a single oral dose of midazolam on Day 1. During the second period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. There is a washout period of 14 to 21 days between the two periods.
Drug: Midazolam · Drug: Selexipag
Subjects participate in two study periods: During the first period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. During the second period, they receive a single oral dose of midazolam on Day 1. There is a washout period of 14 to 21 days between the two periods.
Drug: Midazolam · Drug: Selexipag
Cmax of midazolam following administration of midazolam alone and in combination with selexipag
Cmax is the maximum observed plasma concentration and is directly derived from the individual plasma concentration time curves of midazolam
Time frame: From pre-dose up to 24 hours after midazolam admisnitration for each treatment period
AUC(0-inf) of midazolam following administration of midazolam alone and in combination with selexipag
AUC(0-inf) is the area under the plasma concentration-time curves of midazolam, calculated from time 0 (pre-dose) to the extrapolated infinite time
Time frame: From pre-dose up to 24 hours after midazolam admisnitration for each treatment period
Cmax of 1-hydroxymidazolam following administration of midazolam alone and in combination with selexipag
Time frame: From pre-dose up to 24 hours after midazolam admisnitration
AUC(0-inf) of 1-hydroxymidazolam following administration of midazolam alone and in combination with selexipag
Time frame: From pre-dose up to 24 hours after midazolam admisnitration
tmax of midazolam and 1-hydroxymidazolam following administration of midazolam alone and in combination with selexipag
tmax is the time to reach Cmax of midazolam and its metabolite (1-hydroxymidazolam), respectively
Time frame: From pre-dose up to 24 hours after midazolam admisnitration
t½ of midazolam and 1-hydroxymidazolam following administration of midazolam alone and in combination with selexipag.
t½ is the terminla half-life of midazolam and its metabolite (1-hydroxymidazolam), and corresponds to the period of time required for the concentration levels of midazolam and its metabolite to be reduced by one-half, respectively
Time frame: From pre-dose up to 24 hours after midazolam admisnitration
Trough concentration of selexipag and its metabolite ACT-333679 at steady-state
Trough concentrations are measured before morning administration of selexipag
Time frame: Days 1, 4, 7, 10,12 and 13
Incidence of treatment-emergent adverse events and serious adverse events
A treatment-emergent AE is any AE temporally associated with the use of a study treatment, whether or not considered related to the study treatment
Time frame: Up to 39 days (from Day 1 of Period 1 to end of study of Period 2)
The record gives a start of Jul 2016, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Midazolam · Selexipag